5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
23 citations
,
March 2019 in “AIDS Care” Remembering to take PrEP is the main challenge, and urine monitoring is a preferred adherence method.
10 citations
,
September 2014 in “European Journal of Dermatology” A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.
October 2023 in “Microorganisms” Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
2 citations
,
November 2025 in “Pharmacology Research & Perspectives” Avacopan may cause unexpected side effects, so early monitoring is important.
38 citations
,
August 1999 in “New England journal of medicine/The New England journal of medicine” Indinavir can cause hair loss and other skin problems.
7 citations
,
March 2002 in “AIDS” Indinavir, especially with vitamin A, may cause bone changes, but switching to nelfinavir can reduce these effects.
1 citations
,
December 2004 in “Hepatology” Tenofovir is more effective than adefovir for resistant hepatitis B, Fibroscan is good for assessing liver damage, regulatory T cells may help hepatitis C persist, and other insights into liver health and disease were found.
22 citations
,
September 2020 in “Journal of the American Academy of Dermatology” Apremilast may be a promising long-term treatment for hidradenitis suppurativa.
41 citations
,
August 2007 in “European Journal of Gastroenterology & Hepatology” A woman's total hair loss from hepatitis C treatment grew back after stopping the medication.
52 citations
,
December 2014 in “Journal of Dermatological Science” Apremilast may help treat hair loss in alopecia areata.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
March 2016 in “International Journal of Infectious Diseases” Peginterferon alpha-2a effectively treats acute hepatitis C in hemodialysed patients, despite some side effects.
12 citations
,
June 2005 in “Journal of the European Academy of Dermatology and Venereology” A man with HIV developed skin and hair issues after starting HIV treatment, which improved with topical treatment.
August 2021 in “Revista Colombiana de Reumatología/Revista Colombiana de Reumatologia” Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
13 citations
,
January 2017 in “Annals of dermatology/Annals of Dermatology” Simvastatin/ezetimibe may help some patients with severe alopecia areata regrow hair.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
May 2019 in “Gastroenterology” Androgen lowering medications don't significantly change HCV-related liver cancer risk in men.
350 citations
,
June 1989 in “The American Journal of Medicine” Itraconazole is potentially effective for treating invasive aspergillosis, but more research is needed.
3 citations
,
September 2020 in “Molecular Brain” The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
6 citations
,
October 2016 in “Journal of Chemotherapy” A man lost all his hair as a rare side effect after hepatitis C treatment.
1 citations
,
September 2022 in “Nepal journal of dermatology, venereology & leprology” Apremilast shows promise for several skin conditions but needs more research.
1 citations
,
October 2025 in “Frontiers in Immunology” Avacopan is generally safe, with some minor side effects like nausea and fatigue.
17 citations
,
February 2011 in “Expert Opinion on Drug Safety” Manage side effects of hepatitis C treatment with dose changes and medications, which may improve patient adherence and treatment success.
April 2010 in “Nature Reviews Urology” 1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
25 citations
,
October 2010 in “Journal of Hepatology” Budesonide alone is less effective than standard treatment for autoimmune hepatitis.